Drug Trial Radar · NCT05816395
Safety and Efficacy of RHH646 for Knee Osteoarthritis
Last checked: Nov 19, 2026Latest source record: Mar 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
82
Actual
Start
May 31, 2023
Primary completion
Feb 24, 2025
Study completion Feb 24, 2025
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Apr 18, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 35 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study was to evaluate the articular cartilage-regenerating capacity of RHH646 in the knee as well as to assess safety and tolerability in participants with knee osteoarthritis.
Conditions
- Osteoarthritis, Knee
Interventions
RHH646Drug
RHH646 capsule for oral use
PlaceboDrug
RHH646 placebo capsule for oral use
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Cartilage Volume in the Index Region of the Target Knee by MRITime frame: Baseline, Week 52
- Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: Adverse events were reported from first dose of study treatment until end of study treatment plus follow up period, up to a maximum duration of approximately 56 weeks.
Locations
10 sites in 5 countries. Site status is shown where the registry gives one.
Clinical Trials Research
Lincoln, California
Conquest Research
Winter Park, Florida
Clinical Trial Network
Houston, Texas
Pioneer Research Solutions
Sugar Land, Texas
Novartis Investigative Site
Buenos Aires, Argentina
Novartis Investigative Site
Caba, Argentina
Novartis Investigative Site
Gandrup, Denmark
Novartis Investigative Site
Herlev, Denmark
Novartis Investigative Site
Warsaw, Poland
Novartis Investigative Site
Santiago, A Coruna, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.